dc.contributor.author | Branstetter, Lee | |
dc.contributor.author | Chatterjee, Chirantan | |
dc.contributor.author | Higgins, Matthew J. | |
dc.date.accessioned | 2022-12-30T09:44:21Z | |
dc.date.available | 2022-12-30T09:44:21Z | |
dc.date.issued | 2022-12-01 | |
dc.identifier.citation | Branstetter, L., Chatterjee, C., & Higgins, M. J. (2022). Generic competition and the incentives for early-stage pharmaceutical innovation. Research Policy, 51(10), 104595. https://doi.org/10.1016/J.RESPOL.2022.104595 | en_US |
dc.identifier.issn | 0048-7333 | |
dc.identifier.uri | http://hdl.handle.net/11718/26008 | |
dc.description.abstract | What impact has rising generic competition had on the nature and direction of pharmaceutical innovation? We find broad-based, strong evidence that pharmaceutical companies have diverted their new drug development efforts away from therapeutic markets already well-served by generic drugs. We also find that increasing generic competition induces firms to shift their R&D activity toward more biologic-based products and away from chemical-based products. We conclude by discussing potential implications of our results for long-run innovation policy. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier | en_US |
dc.relation.ispartof | Research Policy | en_US |
dc.subject | Pharmaceutical innovation | en_US |
dc.subject | Generic entry | en_US |
dc.subject | Nature of innovation | en_US |
dc.subject | Innovation policy | en_US |
dc.title | Generic competition and the incentives for early-stage pharmaceutical innovation | en_US |
dc.type | Article | en_US |